Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.
- 1 December 1992
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 89 (23) , 11209-11213
- https://doi.org/10.1073/pnas.89.23.11209
Abstract
We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) infection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 microM concentration. Variations in antiviral activity were seen among the different oligonucleotides, revealing an effect of target selection. Mismatched or random oligonucleotide phosphorothioates delayed, but did not completely inhibit, HIV-1 replication. In the case of inhibition by a splice-acceptor-site antisense oligodeoxynucleotide, a break-through phenomenon occurred after 25 days of treatment, suggesting the development of an "escape mutant." This result did not occur when the inhibitory oligodeoxynucleotides were complementary to the primary-sequence areas of the rev-responsive element and rev-1 genes. Sequential treatment of HIV-1-infected cells with a combination of different antisense oligonucleotides, each administered once, also prevented the development of escape mutants. Our results suggest that chemotherapy based on specifically targeted antisense-oligonucleotide phosphorothioates may be an effective method for reducing the viral burden in HIV-1-infected individuals at clinically achievable oligonucleotide concentrations.Keywords
This publication has 21 references indexed in Scilit:
- Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replicationCell, 1990
- Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA.Proceedings of the National Academy of Sciences, 1990
- HIV-1 structural gene expression requires binding of the rev trans-activator to its RNA target sequenceCell, 1990
- Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues.Proceedings of the National Academy of Sciences, 1989
- Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.Proceedings of the National Academy of Sciences, 1989
- Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.Proceedings of the National Academy of Sciences, 1988
- Inhibition of Replication of the Etiologic Agent of Acquired Immune Deficiency Syndrome (Human T-Lymphotropic Retrovirus/Lymphadenopathy-Associated Virus) by Avarol and Avarone2JNCI Journal of the National Cancer Institute, 1987
- Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.Proceedings of the National Academy of Sciences, 1986
- Trans -Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)Science, 1985
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985